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Abstract
Objectives: To assess the association of gender with clinical expression, health-related quality of life (HRQoL), disability, and
self-reported symptoms of depression and anxiety in patients with systemic sclerosis (SSc).
Methods: SSc patients fulfilling the American College of Rheumatology and/or the Leroy and Medsger criteria were
assessed for clinical symptoms, disability, HRQoL, self-reported symptoms of depression and anxiety by specific
measurement scales.
Results: Overall, 381 SSc patients (62 males) were included. Mean age and disease duration at the time of evaluation were
55.9 (13.3) and 9.5 (7.8) years, respectively. One-hundred-and-forty-nine (40.4%) patients had diffuse cutaneous SSc (dcSSc).
On bivariate analysis, differences were observed between males and females for clinical symptoms and self-reported
symptoms of depression and anxiety, however without reaching statistical significance. Indeed, a trend was found for
higher body mass index (BMI) (25.0 [4.1] vs 23.0 [4.5], p=0.013), more frequent dcSSc, echocardiography systolic pulmonary
artery pressure .35 mmHg and interstitial lung disease in males than females (54.8% vs 37.2%, p=0.010; 24.2% vs 10.5%,
p=0.003; and 54.8% vs 41.2%, p=0.048, respectively), whereas calcinosis and self-reported anxiety symptoms tended to be
more frequent in females than males (36.0% vs 21.4%, p=0.036, and 62.3% vs 43.5%, p=0.006, respectively). On
multivariate analysis, BMI, echocardiography PAP.35 mmHg, and anxiety were the variables most closely associated with
gender.
Conclusions: In SSc patients, male gender tends to be associated with diffuse disease and female gender with calcinosis and
self-reported symptoms of anxiety. Disease-associated disability and HRQoL were similar in both groups.
Citation: Nguyen C, Be ´rezne ´ A, Baubet T, Mestre-Stanislas C, Rannou F, et al. (2011) Association of Gender with Clinical Expression, Quality of Life, Disability, and
Depression and Anxiety in Patients with Systemic Sclerosis. PLoS ONE 6(3): e17551. doi:10.1371/journal.pone.0017551
Editor: Ulrich Thiem, Marienhospital Herne - University of Bochum, Germany
Received October 23, 2010; Accepted February 8, 2011; Published March 9, 2011
Copyright:  2011 Nguyen et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: The authors have no support or funding to report.
Competing Interests: The authors have declared that no competing interests exist.
* E-mail: luc.mouthon@cch.aphp.fr
Introduction
Systemic sclerosis (SSc) is a connective-tissue disease character-
ized by excessive collagen deposition in the dermis and internal
organs, and by vascular hyper-reactivity and obliterative micro-
vascular phenomena [1]. SSc is responsible for diminished life
expectancy, related to skin extent and visceral involvement [2].
SSc is also responsible for tendon, joint, and vessel damage,
leading to disability, handicap, and impaired health-related quality
of life (HRQoL) [3]. In addition, psychiatric symptoms, including
anxiety and depression, have been reported as a consequence of
disease chronicity in SSc patients, with a prevalence of depressive
symptoms ranging from 18% to 65% [4,5,6,7,8,9,10,11,12].
Consistent with other auto-immune diseases, SSc is predomi-
nant among females, with a ratio of females to males of 1:1 to 14:1
[13], along with gender differences in disease activity and
incidence. Such differences have been explained by genetic and
hormonal factors and lifestyle [14,15]. Male gender is usually
considered a factor of poor prognosis in SSc [16,17]. A cohort of
91 SSc patients (10% males) from Spain revealed clinical and
immunological differences between the genders; arthralgias were
more often encountered in females, whereas myositis and
nucleolar antinuclear antibodies were more frequent in males
[15]. More recently, as compared with female SSc patients, males
were found to more often exhibit renal failure, increased blood
pressure, arrythmia and inflammatory myopathy and less often
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and mortality also differed between the sexes [18]. In a large
European cohort of 1180 patients with early SSc (19% males),
features of diffuse disease were significantly more frequent in males
[19]. Recently, Hudson et al. found that the time to diagnosis was
longer for women than men after the onset of Raynaud’s
phenomenon, and suggested that there may be possible biologic
differences in the progression of disease or in the health care
trajectories of men and women with early SSc [20].
Although gender differences in disease-related clinical manifesta-
tions are well established, few studies have compared HRQoL,
disability, and psychiatric symptoms between male and female
patients with SSc. In the present study, we aimed to assess the
association of gender with clinical expression, HRQoL, disability, and
self-reported symptoms of depression and anxiety in patients with SSc.
Methods
Study design
We performed a cross-sectional survey of 381 patients. Patients
with SSc were prospectively included during 7 consecutive annual
meetings of the French SSc patients’ association, the ‘‘Association
des Scle ´rodermiques de France’’ (ASF), between 2003 and 2009,
or during their hospitalization in the internal medicine depart-
ments of Cochin (between January 2006 and June 2009) or Claude
Huriez (between January and June 2009) hospitals. Since some
patients were evaluated during several ASF annual meetings, only
the most recent assessment of each patient was considered.
Patients had to complete self-administered questionnaires first and
then to undergo an interview with a physician to check for
unanswered question, fully complete questionnaires, and gather
clinical data.
Patients
To be eligible for the study, patients had to fulfil the American
College of Rheumatology [21] and/or the Leroy and Medsger
[22] criteria for SSc. Patients from the ASF were assessed within
48 hr during spring (temperature 20uC). Parameters recorded
were age; sex; age at disease onset; disease duration; body mass
index (BMI); disease subset (limited SSc [lSSc], limited cutaneous
SSc [lcSSc] or diffuse cutaneous SSc [dcSSc]); mouth opening
(inter-incisor distance measured in millimetres); skin involvement;
telangiectasia; Raynaud’s phenomenon; pitting scars; digital
ulcers; calcinosis; gastrointestinal tract, joint and/or muscle
involvement; dyspnoea (assessed by the New York Heart
Association [NYHA] 4-point scale); ILD; echocardiography
systolic pulmonary artery pressure [PAP].35 mmHg); and renal
crisis. History of esophagus, gastrointestinal, joint, muscle and/or
heart involvement; ILD; echocardiography PAP.35 mmHg; and
renal crisis was obtained from detailed clinical charts for
hospitalized patients and self-reports for ASF members.
Health status
Health status was assessed by the KPS score, the scale ranging
from 0 (dead) to 100 (normal no complaints; no evidence of
disease) [23]. Originally developed for cancer patients, because it
strongly predicted cancer outcome [24,25], the KPS score has
been shown to provide clinical estimates of patient’s physical state,
performance, and prognosis and to be associated with social status
in patients with SSc [23,26].
Health-related quality of life
HRQol was assessed by the French version of the Medical
Outcomes Study 36-Item Short Form Health Survey (SF-36) [27],
a self-administered questionnaire covering 8 areas: physical
function, physical role, bodily pain, general health, vitality, social
function, emotional role, and mental health. For each area, scores
range from 0 (poorer health status) to 100 (better health status).
Scores can also be summarized in 2 global scores: physical
component score (PCS) and mental component score (MCS).
Disability
Global disability. Global disability was assessed by use of the
standard disability index of the Health Assessment Questionnaire
(HAQ-DI) that contains 20 items (each scored ranging from 0 [no
disability] to 3 [maximal disability]), divided into 8 domains [28].
Patients’ perceived disability. Patients’ perceived disability
was assessed by the McMaster Toronto Arthritis Patient
Preference Disability Questionnaire (MACTAR) [29]. Patients
were asked to select the 3 situations among activities of daily living
(ADL) that caused them maximal trouble [23]. Each item is scored
on an 11-point quantitative scale (range 0–10). The global score
ranges from 0 (no disability) to 30 (maximal disability). This score
has been validated in SSc [23,30].
Hand disability. Hand disability was assessed by the Cochin
Hand Function Scale (CHFS) [31], a questionnaire administered by
the physicianthatcontains18itemsrelatedtoADL.Eachquestion is
scored on a scale of 0 (performed without difficulty) to 5 (impossible
to do). The total score is obtained by adding the scores of all items
(range 0–90). This questionnaire has been validated in SSc [32].
Mouth disability. Mouth disability was assessed by the
Mouth Handicap In Systemic Sclerosis (MHISS) scale, a ques-
tionnaire administered by the physician that contains 12 items
concerning difficulties in performing ADL. Each question is scored
on a scale of 0 (never) to 4 (always) [33]. The total score is obtained
by adding the scores of all items (range 0–48).
Anxiety and depression
Self-reported anxiety and depression symptoms were assessed
by the Hospital Anxiety and Depression scale (HADS). This scale
has 7 questions for the anxiety dimension (HADa) and 7 for the
depression dimension (HADd) [34]. Each item is scored on a scale
of 0 to 3, the total score ranging from 0 (no depression, no anxiety)
to 21 (maximal depression, maximal anxiety). Scores of 0–7 in
subscales are considered normal, 8–10 borderline and $11
pathologic cases [35]. The definition of clinical anxiety and/or
depression was based on the HADS score cutoff $8 found to be
relevant in patients with autoimmune diseases [36].
Aesthetic impairment
Aesthetic impairment was assessed on an 11-point quantitative
scale, the total score ranging from 0 (no aesthetic impairment) to
10 (maximal aesthetic impairment).
Statistical analysis
Data analysis involved use of Systat 9 (SPSS Inc., Chicago, IL,
USA). Quantitative variables were described with means 6
standard deviations (SD) and qualitative variables with frequencies
and percentages. For bivariate analysis, parametric tests were used
since all parameters met criteria for normal distribution.
Comparisons between male and female groups involved the
Pearson chi-square test for qualitative variables and two-sample t
test for quantitative data. Bonferroni adjustment was used for
multiple comparisons (43 comparisons); therefore a p value less
than 0.001 was considered statistically significant. Multivariate
analysis was used to determine the association of gender and SSc-
related variables. Backward stepwise regression all-inclusive
analysis was run, including all dependent variables, with values
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and type of recruitment from either patient association or
hospitalization was performed. Odds ratios (OR) and 95%
confidence intervals were calculated.
Ethics statement
This survey was conducted in compliance with the protocol of
Good Clinical Practices and Declaration of Helsinki principles.
Patients gave their consent to participate after being orally
informed about the study protocol. In accordance with European
regulation (Directive 2001/20/EC of the European Parliament
and of the Council of 4 April 2001 on the approximation of the
laws, regulations and administrative provisions of the Member
States relating to the implementation of good clinical practice in
the conduct of clinical trials on medicinal products for human use;
Directive 95/46/EC of the European Parliament and of the
Council of 24 October 1995 on the protection of individuals with
regard to the processing of personal data and on the free
movement of such data), French observational studies from data
obtained without any additional therapy or monitoring procedure,
do not need formal approval of an Institutional Review Board or
an Independent Ethics Committee, and a formal written consent
from the patients is not required for this kind of project.
Results
Demographic and clinical data
Overall, 381 patients were included. One-hundred-and-forty-
three of them were recruited during their hospitalization in the
internal medicine departments of Cochin (n=127) or Claude
Huriez (n=16) hospitals, and the remaining 238 patients were
recruited during ASF annual meetings from 2003 to 2009. The
proportion of patients from the ASF who agreed among those who
were asked to participate were 51 among 80 (63.8%) (44 females)
in 2003, 50 among 80 (62.5%) (44 females) in 2004, 71 among 98
(72.4%) (59 females) in 2005, 70 among 95 (73.7%) (55 females) in
2006, 70 among 101 (69.3%) (55 females) in 2007, 86 among 130
(66.1%) (74 females) in 2008 and 2009 alltogether. Of the 381
patients, 62 were males (16.4%), with a female to male ratio of 5:1.
The mean age at the time of evaluation was 55.9 (13.3) years, and
mean disease duration was 9.5 (7.8) years. A total of 149 (40.4%)
patients had dcSSc, 187 (50.7%) had lcSSc, and 34 (9.2%) had
lSSc. The mean KPS was 77.6 [11.7] (range 50–100) (Table 1).
Association of gender with SSc clinical expression
Males and females were comparable in age at the time of evaluation
and at disease onset, disease duration and health status as assessed by
the KPS score. For other clinical variables, some differences were
observed between males and females, without reaching statistical
significance. Indeed, BMI was higher in males than females (25.0 [4.1]
vs 23.0 [4.5], p=0.013) (Table 2). DcSSc was more frequent in males
(54.8 vs 37.2%, p=0.010), whereas lSSc was more frequent in females
(10.7% vs 1.6%, p=0.024). Regarding visceral involvement, males
more often exhibited ILD and echocardiography PAP.35 mmHg
than did females (54.8% vs 41.2%, p=0.048; and 24.2% vs 10.5%,
p=0.003, respectively), and females more often calcinosis than males
(36.0% vs 21.4%, p=0.036). On multivariate logistic regression,
gender was significantly associated with BMI (OR 1.12, 95%
confidence interval [CI] 1.01–1.24) and echocardiography PAP.
35 mmHg (OR 0.23, 95% CI 0.07–0.76).
Association of gender with SSc HRQoL and disability
HRQol assessed by the SF-36 was comparable in both groups. PCS
and MCS were similar, and lower than 40 out of 100, for both males
and females (34.2 [10.0] and 35.9 [9.6], p=0.240, and 35.1 [12.3] and
34.3 [13.0], p=0.667, respectively). Consistently, regarding global,
patient-perceived, and location-specific disability as assessed by the
HAQ, MACTAR, and CHFS and MHISS, respectively, we found no
gender differences within each of these variables. Both groups exhibited
similar aesthetic impairment (Table 3).
Association of gender with SSc self-reported symptoms
of depression and anxiety
On bivariate analysis, some differences were observed between
males and females for self-reported symptoms of depression and
anxiety, but without reaching statistical significance. Indeed, self-
reported symptoms of anxiety, as defined by HADa subscale score
$8 were more frequent in females than males (62.3% vs 43.5%,
p=0.006), whereas absence of self-reported symptoms of both
depression and anxiety, as defined by HADa and HADd subscale
scores ,8 was more often encountered in males than females (46.8
vs 31.6%, p=0.021) (Table 4). Males and females did not differ in
depression symptoms. On multivariate analysis, gender was
associated with anxiety only (OR 5.50, 95% CI 1.12–27.04).
Discussion
In the present study of 381 patients with SSc, we found a ratio
of females to males of 5 to 1, which is in agreement with previous
Table 1. Demographic and clinical characteristics of patients
with SSc*.
Age, years, mean (SD) 55.9 (13.3)
Age at disease onset, years, mean (SD) 46.2 (12.9)
Male sex 62/379 (16.4)
Patient association 62/191 (32.5)
Disease duration, years, mean (SD) 9.5 (7.8)
Body mass index, kg/m
2, mean (SD) 23.4 (4.5)
Diffuse cutaneous SSc 149/369 (40.4)
Limited cutaneous SSc 187/369 (50.7)
Limited SSc 34/369 (9.2)
KPS (0–100), mean (SD) 77.6 (11.7)
Inter-incisor distance, mm, mean (SD) 35.9 (9.3)
Skin involvement 339/370 (91.6)
Telangiectasia 253/347 (72.9)
Raynaud’s phenomenon 369/377 (97.9)
Pitting scars 221/376 (58.8)
Digital ulcers 170/375 (45.3)
Calcinosis 105/312 (33.7)
Gastrointestinal tract involvement 304/375 (81.1)
Arthralgia 254/375 (67.7)
Myalgia 209/375 (55.7)
Dyspnea, NYHA classification, mean (SD) 2.1 (0.8)
Interstitial lung disease 163/373 (43.7)
Echocardiography systolic PAP.35 mmHg 48/375 (12.8)
Scleroderma renal crisis 34/375 (9.1)
*Values are number/number of patients for whom the data is available (%),
otherwise indicated in parenthesis.
KPS: Karnofsky performance status; NYHA: New York Heart Association; PAP:
pulmonary artery pressure; SD: standard deviation; SSc: systemic sclerosis.
doi:10.1371/journal.pone.0017551.t001
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females for clinical symptoms and self-reported symptoms of
depression and anxiety, however without reaching statistical
significance. Indeed, dcSSc, echocardiography PAP.35 mmHg
and ILD were more often encountered in males, whereas lSSc and
calcinosis were more often encountered in females. Females were
more frequently found with self-reported symptoms of anxiety.
Conversely, we found no association with gender regarding
perceived health status, HRQoL and reported global and
location-specific disability. On multivariate analysis, BMI, echo-
cardiography PAP.35 mmHg, and anxiety were the variables
most closely associated with gender.
The prevalence of dcSSc in male patients was high and
reached 54.8%. DcSSc was more frequent than lcSSc in males.
The exact opposite was observed in females and was more
consistent with previous reports of epidemiology studies of both
male and female SSc patients. In two large US and German
studies, the prevalence of lcSSc and dcSSc among SSc patients
was 66.2% and 33.8%, and 45.5% and 32.7%, respectively
[37,38]. In 3 cohorts of 1,012 Italian, 249 Swedish and 185
Canadian patients, dcSSc was more frequent in males than
females (range from 37% to 67%) [39,40,41]. Conversely, 2
studies from Spain comparing male and female SSc patients
found no gender differences by disease type [15,18]. Finally, from
a recent retrospective French survey of 121 SSc patients, dcSSc
was more frequent in males than in females (22% vs 5%) [42]. In
these last 3 studies, the male sample sizes were rather small (n=9,
n=26 and n=36, respectively).
We found BMI significantly lower in females than in males. This
finding might be of clinical relevance despite lack of clear
explanatory reports. Indeed, in a prospective multiethnic cohort
of 250 SSc patients, low BMI was among the 7 independent
variables predictive of mortality. The authors even hypothesized
that strong association of low BMI with mortality could be an
objective and/or complete surrogate for generalized decondition-
ing or gastro-intestinal involvement [43].
Females were also more likely to have calcinosis, which is a
frequent manifestation of SSc and found in about 25% of patients
[44]. Calcinosis mainly affects the extremities, at sites of recurrent
microtrauma such as the forearms, elbows or fingers [45]. It occurs
predominantly at a late stage of disease and is not restricted to
patients with the lSSc [46]. However, clinical features associated
with calcinosis remain poorly described. Recently, we provided
evidence that calcinosis is an independent factor associated with
digital ulcers (OR 2.33, 95% CI 1.04–5.19) [47].
In agreement with previous studies, we found that men were
more likely than women to have echocardiography PAP.
35 mmHg and ILD, for prevalences of 24.2% and 54.8%,
respectively. Lung involvement is common in the course of SSc,
and together, ILD and pulmonary hypertension are considered the
2 main causes of death in this disease [48]. ILD is more frequent in
male SSc patients at the time of diagnosis and during follow-up
[42]. In addition, male gender is associated with pulmonary
hypertension during follow-up [42]. In 1180 SSc patients (19%
men) studied at early stages of the disease, men more often than
women were found to have lung fibrosis and lower diffusing lung
Table 2. Association of gender with clinical manifestations in SSc*.
Males
n=62
Females
n=319 p-value
{
Age, years (mean [SD]) 55.7 (14.5) 55.9 (13.1) 0.924
Age at disease onset, years (mean [SD]) 46.7 (14.4) 46.1 (12.7) 0.749
Disease duration, years (mean [SD]) 8.9 (6.8) 9.7 (8.1) 0.577
Body mass index, kg/m
2 (mean [SD]) 25.0 (4.1) 23.0 (4.5) 0.013
Diffuse cutaneous SSc 34/62 (54.8) 115/309 (37.2) 0.010
Limited cutaneous SSc 27/62 (43.5) 160/309 (51.8) 0.237
Limited SSc 1/62 (1.6) 33/309 (10.7) 0.024
KPS (0–100) (mean [SD]) 78.0 (11.6) 77.5 (11.7) 0.755
Inter-incisor distance, mm (mean [SD]) 37.0 (9.4) 35.7 (9.3) 0.359
Skin involvement 59/62 (95.2) 280/310 (90.3) 0.221
Telangiectasias 46/60 (76.7) 207/289 (71.6) 0.426
Raynaud’s phenomenon 59/62 (95.2) 310/317 (97.8) 0.237
Pitting scars 41/62 (66.1) 180/316 (57.0) 0.180
Digital ulcers 28/61 (45.9) 142/316 (44.9) 0.890
Calcinosis 12/56 (21.4) 93/258 (36.0) 0.036
Gastrointestinal tract involvement 50/62 (80.6) 254/315 (80.6) 0.999
Arthralgias 39/62 (62.9) 215/315 (68.3) 0.411
Myalgias 32/62 (51.6) 177/315 (56.2) 0.507
Dyspnea, NYHA classification (mean [SD]) 2.2 (0.8) 2.0 (0.9) 0.190
Interstitial lung disease 34/62 (54.8) 129/313 (41.2) 0.048
Echocardiography systolic PAP.35 mmHg 15/62 (24.2) 33/315 (10.5) 0.003
Scleroderma renal crisis 8/62 (12.9) 26/315 (8.3) 0.243
*Values are number/number of patients for whom the data is available (%), otherwise indicated in parenthesis.
SSc: systemic sclerosis; SD: standard deviation; KPS: Karnofsky Performance Status; NYHA: New York Heart Association; PAP: pulmonary artery pressure.
doi:10.1371/journal.pone.0017551.t002
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involvement in male SSc patients requires special attention and
specific care because of its frequency and association with poor
prognosis.
Interestingly, we found gender differences for both self-reported
symptoms of depression and anxiety in SSc. Females more often
exhibited self-reported symptoms of anxiety, whereas men were
more often free of self-reported symptoms of both anxiety and
depression. In a recent cross-sectional survey of 108 patients
visiting a rheumatology outpatient department, the only factor
significantly associated with psychiatric symptoms was gender
[49]. Conversely, in another cross-sectional study of 111 patients
visiting a rheumatology clinic, 9% with SSc, gender had no effect
on the frequency of anxiety and depression [50]. Finally, in a study
designed to assess psychological adjustment of 112 patients with
early polyarthritis, female gender was found to be associated with
high levels of depression and anxiety [51]. Substantial evidence
indicates that females report greater fear and are more likely to
have anxiety disorders than are males. Complex processes underlie
gender differences in anxiety. Individual differences in etiological
factors of anxiety and fear are moderated by socialization
processes that prescribe gender-specific expectations for expression
of anxiety and the acceptable means of coping with anxiety [52].
Finally, we found no differences in depression symptoms by gender
(40.3 vs 40.8%, p=0.96), which is consistent with recent findings
by Thombs et al [12].
Remarkably, despite our finding of gender differences in clinical
expression in SSc, males and females experienced comparable loss
of function, global and location-specific disability, and HRQoL
impairment, as evidenced by similar HAQ, CHFS, MHISS,
MACTAR and SF-36 scores. Gender may not be a major
determinant of perceived disability and impaired HRQoL in
patients with SSc, and functional and social issues should be
considered as severe in males as in females. Consistently, we
Table 3. Association of gender with health-related quality of life and disability in SSc*.
All patients
n=381
Males
n=62
Females
n=319 p-value
{
KPS (0–100) 77.6 (11.7) 78.0 (11.6) 77.5 (11.7) 0.755
SF-36 (0–100)
N Physical functioning 35.7 (24.8) 31.4 (24.7) 36.6 (24.7) 0.152
N Physical role 19.4 (24.8) 15.8 (29.5) 20.1 (31.5) 0.350
N Bodily pain 22.5 (25.7) 19.6 (24.3) 23.1 (25.9) 0.349
N General health perception 24.1 (20.2) 23.9 (22.4) 24.1 (19.8) 0.932
N Vitality 21.9 (20.7) 21.7 (22.6) 21.9 (20.3) 0.973
N Social functioning 30.0 (32.5) 30.4 (34.3) 30.0 (32.2) 0.923
N Emotional role 24.2 (36.5) 24.5 (38.0) 24.1 (36.3) 0.945
N Mental health 32.6 (25.1) 31.6 (27.5) 32.8 (24.7) 0.753
N PCS 34.9 (14.6) 34.2 (10.0) 35.9 (9.6) 0.240
N MCS 38.5 (36.9) 35.1 (12.3) 34.3 (13.0) 0.667
HAQ (0–3) 1.1 (0.8) 1.0 (0.8) 1.1 (0.8) 0.237
MACTAR (0–30) 18.5 (8.2) 18.8 (7.1) 18.4 (8.4) 0.753
CHFS (0–90) 20.1 (19.3) 19.8 (20.3) 20.2 (19.2) 0.890
MHISS (0–48) 19.0 (11.6) 20.4 (15.0) 18.7 (10.7) 0.512
Aesthetic impairment 4.6 (2.6) 4.5 (3.4) 4.6 (2.4) 0.833
*Values are the mean (standard deviation).
SSc: systemic sclerosis; KPS: Karnofsky Performance Status Scale; SF-36: Medical Outcomes Study 36-Item Short Form Health Survey; PCS: Physical Component Score;
MCS: Mental Component Score; HAQ: Health Assessment Questionnaire; MACTAR: McMaster-Toronto Arthritis Patient Preference Disability Questionnaire; CHFS: Cochin
Hand Function Scale; MHISS: Mouth Handicap In Systemic Sclerosis Scale.
doi:10.1371/journal.pone.0017551.t003
Table 4. Association of gender with depression and anxiety in SSc*.
All patients
n=381
Males
n=62
Females
n=319 p-value
{
HADa (0–21) (mean [SD]) 9.2 (4.5) 8.3 (5.1) 9.4 (4.4) 0.088
N HADa$8 224/378 (59.3) 27/62 (43.5) 197/316 (62.3) 0.006
HADd (0–21) (mean [SD]) 6.6 (4.2) 6.5 (4.6) 6.6 (4.1) 0.781
N HADd$8 154/378 (40.7) 25/62 (40.3) 129/316 (40.8) 0.957
N HADa and HADd,8 129/378 (34.1) 29/62 (46.8) 100/316 (31.6) 0.021
*Values are number/number of patients for whom the data is available (%), otherwise indicated in parenthesis.
SSc: systemic sclerosis; n: number; HADa: Hospital Anxiety and Depression scale for Anxiety; HADd: Hospital Anxiety and Depression scale for Depression.
doi:10.1371/journal.pone.0017551.t004
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strongly associated with perceived disability and health status but
not with gender [26]. In addition, using the World Health
Association Disability Assessment Schedule II to assess HRQoL,
Hudson et al found that clinical correlates of HRQoL did not
include gender [53]. HRQoL and functional disability may be
associated with the meaning that SSc patients ascribe to their
condition, which may be comparable for both males and females,
rather than with its severity or its organ manifestation.
Our work has some limitations. Our sample of males was small,
and our inability to demonstrate statistically significant differences
between the two groups might be due to the lack of statistical
power. Another limitation was the procedure used to recruit
patients. Since all patients belonged to the French association of
patients or were hospitalized in tertiary care units, they may not be
representative of the whole French SSc population. Patients had
longstanding disease, which could imply more symptoms. HAQ
scores were high but remained comparable to those reported from
previous studies conducted in tertiary care settings [54]. Moreover,
patients recruited from the patient association may have had more
severe SSc than hospitalized patients [55]. Further studies
conducted in other cohorts are required to confirm the gender
differences we observed. Finally, our study was not designed to
explore the reasons for the observed gender differences. One can
only hypothesize about the associated etiological factors, which
may involve hormonal influences; genetics such as X-chromosome
inactivation and monosomy, or microchimerism; as well as lifestyle
(e.g., the debated connection with silicone implants) [14].
In conclusion, we confirm the association of gender and clinical
manifestations in patients with SSc. Diffuse disease and lung
involvement are more frequent in males, whereas females more
often exhibit calcinosis and self-reported symptoms of anxiety.
Despite SSc patients displaying gender-related clinical differences,
the disease impact on perceived health status, HRQol and
disability, is comparable in both groups. Studies comparing male
and female patients living in different countries, with different
occupational, lifestyle and medical exposure, would also be of
interest to further clarify the role of environmental factors in such
gender differences.
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